Peter Lin MD, CCFPDirector, Primary Care Initiatives, Canadian Heart Research Centre, Ontario, Canada
Dr. Peter Lin began his studies in the Faculty of Science and Engineering at the University of Toronto in Toronto, Ontario. Midway through, he moved to the Faculty of Medicine, where he completed his studies and became involved in research. Over the years, it became apparent to him that there was a wide chasm between research and clinical practice, and he moved into clinical practice in primary care and eventually into teaching in order to help bridge this gap. He served as the medical director at the Health & Wellness Centre, University of Toronto Scarborough, for 7 years.
Currently, Dr. Peter Lin is the Director of Primary Care Initiatives at the Canadian Heart Research Centre. He is also a contributing author to the Canadian Diabetes Guidelines 2013 and 2018 on the vascular protection section. He is also Associate Editor for the Elsevier WebPortal - PracticeUpdate Primary Care. He lectures and speaks internationally on a variety of topics. Dr. Lin has worked with KDIGO in order to help improve care for CKD patients. He has also been tracking and providing information on COVID-19 to the public since the beginning of the pandemic. Dr. Lin received a teaching award from the College of Family Physicians in 2011.
DisclosuresDr. Lin has consulted with the following companies on Continuing Medical Education programs:
Astrazeneca, Boeringher Ingelheim, Bayer, Eli Lilly, Amgen, Janssen, Merck, Pfizer, Sanofi, Abbott, HLS Therapeutics Inc.
No clinical trials. No patents.
Recent Contributions to PracticeUpdate:
- Association of Vitamin D Supplementation With Risk of Incident Fractures in Middle-Aged and Older Adults
- Association of OSA With White Matter Integrity and Cognitive Performance in Middle to Late Adulthood
- Accuracy of Smartwatches for Detecting Atrial Fibrillation
- Role of a Single hs-cTnT Measurement in Excluding Acute Myocardial Injury and Infarction in the Emergency Department
- Oral Contraceptive Use, Hormone Replacement Therapy, and Stroke Risk
- Efficacy and Safety of Intramuscular Administration of Tixagevimab–Cilgavimab for Early Outpatient Treatment of COVID-19
- Preconception Antidiabetic Drugs in Men and Birth Defects in Offspring
- Association of Menopausal Hormone Therapy Formulation With Breast Cancer Risk
- Nighttime MUCH Is Associated With Adverse Cardiovascular and Kidney Outcomes in Patients With CKD Not Receiving Dialysis
- Multicomponent Intervention Decreased Mobility Disability in Frail Older Adults